- Conditions
- Diabetes Mellitus, Type 1 Diabetes
- Interventions
- AHEAD Program
- Behavioral
- Lead sponsor
- University of British Columbia
- Other
- Eligibility
- 16 Years to 19 Years
- Enrollment
- 306 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 1
- States / cities
- Seattle, Washington
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 73–96
of 1,427
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Insulin Response, Type 1 Diabetes
- Interventions
- Standardized meal 1
- Other
- Lead sponsor
- Texas A&M University
- Other
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- College Station, Texas
- Conditions
- Type 1 Diabetes Mellitus
- Interventions
- Humalog, Novolog, BC222 insulin lispro, Bionic Pancreas
- Drug · Device
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
- Interventions
- ELG
- Device
- Lead sponsor
- XP Technology, LLC
- Other
- Eligibility
- 25 Years to 65 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 1
- States / cities
- Springdale, Arkansas
- Conditions
- Type1 Diabetes Mellitus
- Interventions
- Beta Cell Loss and Immune Function, Immune Function with RNAseq
- Diagnostic Test · Other
- Lead sponsor
- University of Exeter
- Other
- Eligibility
- Up to 70 Years
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2028
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Diabetes Mellitus, Type 1
- Interventions
- Blood Glucose Awareness Training for Parents
- Behavioral
- Lead sponsor
- University of Virginia
- Other
- Eligibility
- 6 Years to 11 Years
- Enrollment
- 77 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts • Charlottesville, Virginia
- Conditions
- Diabetes Mellitus, Type 1
- Interventions
- MYL-1601D Product, FlexPen NovoLog®
- Drug
- Lead sponsor
- Mylan Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 478 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 158
- States / cities
- Montgomery, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 125 more
- Conditions
- Diabetes Mellitus, Type 1
- Interventions
- Motivational Enhancement System (MES), Question Prompt List (QPL), Text Message Reminders (TXT)
- Behavioral
- Lead sponsor
- Wayne State University
- Other
- Eligibility
- 16 Years to 25 Years
- Enrollment
- 113 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2025
- U.S. locations
- 1
- States / cities
- Detroit, Michigan
- Conditions
- Diabetes Mellitus Type 1
- Interventions
- Allogeneic Pancreatic Endocrine Cell Clusters
- Biological
- Lead sponsor
- Seraxis
- Industry
- Eligibility
- 18 Years to 65 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 2
- States / cities
- Philadelphia, Pennsylvania • Pittsburgh, Pennsylvania
- Conditions
- Type 1 Diabetes Mellitus
- Interventions
- Insulin glargine,300 U/mL, Insulin glargine (100 units /mL), Background therapy
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 6 Years to 17 Years
- Enrollment
- 463 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 13
- States / cities
- Tucson, Arizona • Atlanta, Georgia • Indianapolis, Indiana + 9 more
- Conditions
- Type 1 Diabetes
- Interventions
- Fit Families plus Standard Medical Care
- Behavioral
- Lead sponsor
- Wayne State University
- Other
- Eligibility
- 10 Years to 17 Years
- Enrollment
- 49 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 1
- States / cities
- Detroit, Michigan
- Conditions
- Diabetes Mellitus, Type 1
- Interventions
- Observational
- Other
- Lead sponsor
- Nemours Children's Clinic
- Other
- Eligibility
- 7 Years to 16 Years
- Enrollment
- 221 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2018
- U.S. locations
- 5
- States / cities
- Palo Alto, California • New Haven, Connecticut • Jacksonville, Florida + 2 more
- Conditions
- Type 1 Diabetes
- Interventions
- Insulin Degludec, Insulin Glargine, Placebo
- Drug
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 59 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2023
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Type 1 Diabetes
- Interventions
- Control-IQ Technology v1.5
- Device
- Lead sponsor
- Tandem Diabetes Care, Inc.
- Industry
- Eligibility
- 2 Years to 5 Years
- Enrollment
- 144 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- San Diego, California
- Conditions
- Islet Transplantation, Type1 Diabetes Mellitus
- Interventions
- Continuous Glucose Monitor (CGM)
- Other
- Lead sponsor
- University of Virginia
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 1
- States / cities
- Charlottesville, Virginia
- Conditions
- Diabetes Mellitus, Type 1
- Interventions
- Abrocitinib 200 MG Oral Tablet, Ritlecitinib, Placebo
- Drug
- Lead sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- NIH
- Eligibility
- 12 Years to 35 Years
- Enrollment
- 78 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 23
- States / cities
- Orange, California • Palo Alto, California • San Francisco, California + 20 more
- Conditions
- Type 1 Diabetes Mellitus
- Interventions
- Not listed
- Lead sponsor
- Metabolic Research Institute, Inc.
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2021
- U.S. locations
- 1
- States / cities
- West Palm Beach, Florida
- Conditions
- Type 1 Diabetes
- Interventions
- Belatacept and Raptiva
- Drug
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2016
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Type 1 Diabetes
- Interventions
- Resveratrol, Placebo
- Drug · Other
- Lead sponsor
- Augusta University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2027
- U.S. locations
- 1
- States / cities
- Augusta, Georgia
- Conditions
- Diabetes Mellitus, Type 1
- Interventions
- Otelixizumab
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 12 Years to 45 Years
- Enrollment
- 88 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2011
- U.S. locations
- 16
- States / cities
- Birmingham, Alabama • Walnut Creek, California • Aurora, Colorado + 13 more
- Conditions
- Diabetes Mellitus, Type 1
- Interventions
- Allogenic islet cells (human, U. Chicago), Intraportal infusion of islet cells
- Biological · Procedure
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- 18 Years to 68 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2026
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Insulin Treated Type 2 Diabetes Mellitus, Diabetes Mellitus, Type 1
- Interventions
- Control:Diabetes mobile app
- Other
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 55 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Diabetes Mellitus, Type 1
- Interventions
- Not listed
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 36 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008 – 2011
- U.S. locations
- 2
- States / cities
- New Haven, Connecticut • Minneapolis, Minnesota
- Conditions
- Type 1 Diabetes (T1D)
- Interventions
- BREATHE-T1D, HealthEd-T1D
- Behavioral
- Lead sponsor
- Children's National Research Institute
- Other
- Eligibility
- 13 Years to 17 Years
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 2
- States / cities
- Aurora, Colorado • Washington D.C., District of Columbia